Victory Capital Management Inc. purchased a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) ...

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.

Live audio webcasts and replays of the TD Cowen fireside event will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Spyre Therapeutics, Inc. (SYRE) on Thursday reported a loss of $56.3 million in its fourth quarter. The Waltham, Massachusetts-based company said it ...

Spyre Therapeutics, Inc. (SYRE) on Thursday reported a loss of $56.3 million in its fourth quarter. The Waltham, Massachusetts-based company said it had ...

Finally, Wedbush restated an “outperform” rating and set a $65.00 price target on shares of Spyre Therapeutics in a report on Monday, January 13th. 10 Stocks to Sell NOW! 3 Stocks to DOUBLE ...

2018 Equity Inducement Plan, as amended (the "2018 Plan"). The stock options were approved on March 3, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with ...

The stock options were approved on March 3, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were ...

JonesTrading analyst Debanjana Chatterjee reiterated a Hold rating on Spyre Therapeutics (SYRE – Research Report) today. The company’s shares ...